Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 6/20 | 0.58 |
| ▸ | FAAH | O00519 | 9/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349917 | 1.00 | MIF (0.58) | MIFFAAHTDP1CTSKCA1 | |
| SCHEMBL12041932 | 0.96 | MIF (0.57) | MIFFAAH | |
| SCHEMBL6838827 | 0.89 | MIF (0.46) | MIFFAAHTDP1CA2 | |
| SCHEMBL2589301 | 0.89 | MIF (0.46) | MIFFAAHTDP1CA2 | |
| SCHEMBL2589303 | 0.89 | MIF (0.46) | MIFFAAHTDP1CA2 | |
| SCHEMBL10553690 | 0.86 | MIF (0.56) | MIFFAAHCA1CA2 | |
| SCHEMBL10553692 | 0.86 | MIF (0.56) | MIFFAAHCA1CA2 | |
| SCHEMBL13499995 | 0.86 | MIF (0.45) | MIFFAAHTDP1CTSKCA2 | |
| SCHEMBL23797233 | 0.85 | MIF (0.76) | MIFFAAHCA1CA2 | |
| SCHEMBL22286018 | 0.85 | MIF (0.43) | MIFFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580746-B2 | Amide linkage cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580747-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580747-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2001518-B1 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-1719768-B1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-1535913-B1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | PALATIN TECHNOLOGIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007115164-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115175-A2 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719768-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050009805-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | ARGLU1, QRFPR, ARG1 | MIF 1688/4885FAAH 2706/4885TDP1 3303/4885 |
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | MIF 3027/4885FAAH 684/4885TDP1 4134/4885 |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | ARGLU1, ARG1, QRFPR | MIF 2374/4885FAAH 1768/4885TDP1 4227/4885 |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | MIF 3323/4885FAAH 2765/4885TDP1 2975/4885 |
| US-20050009805-A1 | Novel quaternary ammonium compounds | SLC10A1, GOT1, ACAT2 | MIF 4600/4885FAAH 297/4885TDP1 3084/4885 |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | MIF 4473/4885FAAH 219/4885TDP1 2209/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | MIF 4348/4885FAAH 123/4885TDP1 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.